Multiple Sclerosis
Conference Coverage
DMT discontinuation trial halted; MS returned in 17.8%
It’s still not clear when – or if – certain patients should take a break from MS therapy.
Feature
Are cellular therapies the future of autoimmune disease?
Promising results from small case studies and early clinical trials hint at the potential of CAR T-cell therapy to treat – and possibly cure –...
Literature Review
New evidence early treatment improves preclinical MS outcomes
“For the first time, we may have an opportunity to better identify those at risk for a primary progressive clinical course at this preclinical...
Conference Coverage
MS drugs during pregnancy show no safety signals
Data on outcomes from cladribine, ocrelizumab, ofatumumab, and ozanimod during pregnancy showed no miscarriages or malformations above the general...
FDA/CDC
FDA okays first biosimilar for multiple sclerosis
“Biosimilar medications offer additional effective treatment options that have the potential to increase access for people living with relapsing...
Literature Review
Early MS treatment tied to a major reduction in severe disability
“With a very early treatment, within 6 months from the first symptoms and even before the MS diagnosis, we are now able to decrease long-term...
Conference Coverage
Retinal thickness a new predictor of MS disability?
The imaging technique cannot be used for all patients and is currently not widely available.
Conference Coverage
Global burden of brain disorders surpasses cardiovascular disease and cancer
“The burden of brain conditions will increase as populations continue to grow and age.”
Conference Coverage
Multiple sclerosis has a misdiagnosis problem
Experts warn that false-negative diagnoses cause treatment delays, while false-positive diagnoses run the risk for potential harm from needless...
Conference Coverage
No apparent drug interaction with ozanimod and antidepressants
Patients with MS who are taking SSRIs or SNRIs had lower rates of hypertension and adverse events potentially related to serotonin than patients...
Conference Coverage
‘Strikingly positive’ effect of novel MS agent
Frexalimab is a novel second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway.